Doctor-patient communication about breast cancer adjuvant therapy

L. A. Siminoff, John H Fetting, M. D. Abeloff

Research output: Contribution to journalArticle

Abstract

Candidates for breast cancer adjuvant therapy must not only grapple with the concept of micrometastatic disease, but often must consider the benefits and risks of clinical trials and alternatives. We studied 100 consecutive patient-physician encounters about adjuvant therapy to determine how well we informed patients about benefits and risks and how clearly we recommended treatment. Evaluation included observation and audiorecording of encounters, patient- and physician-completed questionnaires, and patient interviews. Patient-physician agreement on the benefits and risks of adjuvant therapy was poor. Sixty percent of patients overestimated their chance of cure by 20% or more compared with the physician. Poor agreement was partially explained by the observation that patients and physicians exchanged little specific information. Furthermore, decision-making was compressed. Although this was the first meeting with a medical oncologist for 79 patients (79%), 82 (82%) made final decisions about treatment by the end of the meeting. Physicians clearly identified their recommended treatment. Patients generally followed the physician's recommendation, except when clinical trials were recommended. Only 45% of trial-eligible patients chose to participate in offered trials. Physician recommendations of clinical trials were not as effectively communicated as nontrial treatments. Nonstandard adjuvant regimens, similar to the experimental arm of some ongoing randomized trials, were recommended to 30% of patients, especially those with a poor prognosis. In essence, physicians acted as if the trial question was answered, thereby diminishing enthusiasm for the trial. The widespread recommendation of nonstandard regimens similar or identical to the experimental arms in ongoing trials suggests a serious lack of consensus on what questions to ask in clinical trials and whether or not those questions have been answered.

Original languageEnglish (US)
Pages (from-to)1192-1200
Number of pages9
JournalJournal of Clinical Oncology
Volume7
Issue number9
StatePublished - 1989
Externally publishedYes

Fingerprint

Communication
Breast Neoplasms
Physicians
Clinical Trials
Therapeutics
Consensus
Decision Making
Observation
Interviews

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Doctor-patient communication about breast cancer adjuvant therapy. / Siminoff, L. A.; Fetting, John H; Abeloff, M. D.

In: Journal of Clinical Oncology, Vol. 7, No. 9, 1989, p. 1192-1200.

Research output: Contribution to journalArticle

Siminoff, L. A. ; Fetting, John H ; Abeloff, M. D. / Doctor-patient communication about breast cancer adjuvant therapy. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 9. pp. 1192-1200.
@article{38fcd8024c29462f85237a75e5c32add,
title = "Doctor-patient communication about breast cancer adjuvant therapy",
abstract = "Candidates for breast cancer adjuvant therapy must not only grapple with the concept of micrometastatic disease, but often must consider the benefits and risks of clinical trials and alternatives. We studied 100 consecutive patient-physician encounters about adjuvant therapy to determine how well we informed patients about benefits and risks and how clearly we recommended treatment. Evaluation included observation and audiorecording of encounters, patient- and physician-completed questionnaires, and patient interviews. Patient-physician agreement on the benefits and risks of adjuvant therapy was poor. Sixty percent of patients overestimated their chance of cure by 20{\%} or more compared with the physician. Poor agreement was partially explained by the observation that patients and physicians exchanged little specific information. Furthermore, decision-making was compressed. Although this was the first meeting with a medical oncologist for 79 patients (79{\%}), 82 (82{\%}) made final decisions about treatment by the end of the meeting. Physicians clearly identified their recommended treatment. Patients generally followed the physician's recommendation, except when clinical trials were recommended. Only 45{\%} of trial-eligible patients chose to participate in offered trials. Physician recommendations of clinical trials were not as effectively communicated as nontrial treatments. Nonstandard adjuvant regimens, similar to the experimental arm of some ongoing randomized trials, were recommended to 30{\%} of patients, especially those with a poor prognosis. In essence, physicians acted as if the trial question was answered, thereby diminishing enthusiasm for the trial. The widespread recommendation of nonstandard regimens similar or identical to the experimental arms in ongoing trials suggests a serious lack of consensus on what questions to ask in clinical trials and whether or not those questions have been answered.",
author = "Siminoff, {L. A.} and Fetting, {John H} and Abeloff, {M. D.}",
year = "1989",
language = "English (US)",
volume = "7",
pages = "1192--1200",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Doctor-patient communication about breast cancer adjuvant therapy

AU - Siminoff, L. A.

AU - Fetting, John H

AU - Abeloff, M. D.

PY - 1989

Y1 - 1989

N2 - Candidates for breast cancer adjuvant therapy must not only grapple with the concept of micrometastatic disease, but often must consider the benefits and risks of clinical trials and alternatives. We studied 100 consecutive patient-physician encounters about adjuvant therapy to determine how well we informed patients about benefits and risks and how clearly we recommended treatment. Evaluation included observation and audiorecording of encounters, patient- and physician-completed questionnaires, and patient interviews. Patient-physician agreement on the benefits and risks of adjuvant therapy was poor. Sixty percent of patients overestimated their chance of cure by 20% or more compared with the physician. Poor agreement was partially explained by the observation that patients and physicians exchanged little specific information. Furthermore, decision-making was compressed. Although this was the first meeting with a medical oncologist for 79 patients (79%), 82 (82%) made final decisions about treatment by the end of the meeting. Physicians clearly identified their recommended treatment. Patients generally followed the physician's recommendation, except when clinical trials were recommended. Only 45% of trial-eligible patients chose to participate in offered trials. Physician recommendations of clinical trials were not as effectively communicated as nontrial treatments. Nonstandard adjuvant regimens, similar to the experimental arm of some ongoing randomized trials, were recommended to 30% of patients, especially those with a poor prognosis. In essence, physicians acted as if the trial question was answered, thereby diminishing enthusiasm for the trial. The widespread recommendation of nonstandard regimens similar or identical to the experimental arms in ongoing trials suggests a serious lack of consensus on what questions to ask in clinical trials and whether or not those questions have been answered.

AB - Candidates for breast cancer adjuvant therapy must not only grapple with the concept of micrometastatic disease, but often must consider the benefits and risks of clinical trials and alternatives. We studied 100 consecutive patient-physician encounters about adjuvant therapy to determine how well we informed patients about benefits and risks and how clearly we recommended treatment. Evaluation included observation and audiorecording of encounters, patient- and physician-completed questionnaires, and patient interviews. Patient-physician agreement on the benefits and risks of adjuvant therapy was poor. Sixty percent of patients overestimated their chance of cure by 20% or more compared with the physician. Poor agreement was partially explained by the observation that patients and physicians exchanged little specific information. Furthermore, decision-making was compressed. Although this was the first meeting with a medical oncologist for 79 patients (79%), 82 (82%) made final decisions about treatment by the end of the meeting. Physicians clearly identified their recommended treatment. Patients generally followed the physician's recommendation, except when clinical trials were recommended. Only 45% of trial-eligible patients chose to participate in offered trials. Physician recommendations of clinical trials were not as effectively communicated as nontrial treatments. Nonstandard adjuvant regimens, similar to the experimental arm of some ongoing randomized trials, were recommended to 30% of patients, especially those with a poor prognosis. In essence, physicians acted as if the trial question was answered, thereby diminishing enthusiasm for the trial. The widespread recommendation of nonstandard regimens similar or identical to the experimental arms in ongoing trials suggests a serious lack of consensus on what questions to ask in clinical trials and whether or not those questions have been answered.

UR - http://www.scopus.com/inward/record.url?scp=0024432986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024432986&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 1192

EP - 1200

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -